NovoCure Ltd (NVCR) stock
NVCRNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 9/3027% below fair value
$11.83+0.11 (+0.94%)
Close on Nov 13, 2026Market cap $1.38BP/E –Yield –
NovoCure EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
NovoCure's EPS for the twelve months ending Sep 30, 2026 was -$1.06. For fiscal 2025 it was -$1.22. The highest annual figure on record is $0.18 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$1.22 | – |
| FY2024 | Dec 31, 2024 | -$1.56 | – |
| FY2023 | Dec 31, 2023 | -$1.95 | – |
| FY2022 | Dec 31, 2022 | -$0.88 | – |
| FY2021 | Dec 31, 2021 | -$0.56 | -411.1% |
| FY2020 | Dec 31, 2020 | $0.18 | – |
| FY2019 | Dec 31, 2019 | -$0.07 | – |
| FY2018 | Dec 31, 2018 | -$0.69 | – |
| FY2017 | Dec 31, 2017 | -$0.70 | – |
| FY2016 | Dec 31, 2016 | -$1.54 | – |
| FY2015 | Dec 31, 2015 | -$3.67 | – |
| FY2014 | Dec 31, 2014 | -$6.46 | – |
| FY2013 | Dec 31, 2013 | -$6.73 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$0.09 | – |
| Q2 FY2026 | Jun 30, 2026 | -$0.13 | – |
| Q1 FY2026 | Mar 31, 2026 | -$0.62 | – |
| Q4 FY2025 | Dec 31, 2025 | -$0.22 | – |
| Q3 FY2025 | Sep 30, 2025 | -$0.33 | – |
| Q2 FY2025 | Jun 30, 2025 | -$0.36 | – |
| Q1 FY2025 | Mar 31, 2025 | -$0.31 | – |
| Q4 FY2024 | Dec 31, 2024 | -$0.61 | – |
| Q3 FY2024 | Sep 30, 2024 | -$0.28 | – |
| Q2 FY2024 | Jun 30, 2024 | -$0.31 | – |
| Q1 FY2024 | Mar 31, 2024 | -$0.36 | – |
| Q4 FY2023 | Dec 31, 2023 | -$0.44 | – |
| Q3 FY2023 | Sep 30, 2023 | -$0.46 | – |
| Q2 FY2023 | Jun 30, 2023 | -$0.54 | – |
| Q1 FY2023 | Mar 31, 2023 | -$0.50 | – |
| Q4 FY2022 | Dec 31, 2022 | -$0.36 | – |
| Q3 FY2022 | Sep 30, 2022 | -$0.25 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.23 | – |
| Q1 FY2022 | Mar 31, 2022 | -$0.04 | – |
| Q4 FY2021 | Dec 31, 2021 | -$0.25 | -725.0% |
| Q3 FY2021 | Sep 30, 2021 | -$0.13 | -244.4% |
| Q2 FY2021 | Jun 30, 2021 | -$0.14 | -800.0% |
| Q1 FY2021 | Mar 31, 2021 | -$0.04 | -200.0% |
| Q4 FY2020 | Dec 31, 2020 | $0.04 | 0.0% |
| Q3 FY2020 | Sep 30, 2020 | $0.09 | +350.0% |
| Q2 FY2020 | Jun 30, 2020 | $0.02 | – |
| Q1 FY2020 | Mar 31, 2020 | $0.04 | – |
| Q4 FY2019 | Dec 31, 2019 | $0.04 | – |
| Q3 FY2019 | Sep 30, 2019 | $0.02 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.01 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.13 | – |
| Q4 FY2018 | Dec 31, 2018 | -$0.17 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.13 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.17 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.23 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.12 | – |
| Q3 FY2017 | Sep 30, 2017 | -$0.13 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.24 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.21 | – |
| Q4 FY2016 | Dec 31, 2016 | -$0.26 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?